Roche completes acquisition of TIB Molbiol
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
It’s a two-dose vaccine administered 28 days apart
The aim is to create an awareness programme that will drive diabetic patients to get their eyes tested regularly
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
It is estimated that one-third of our country’s population has some form of these disorders
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
Subscribe To Our Newsletter & Stay Updated